What this is
- This research presents a novel () system that operates without inducers.
- The system utilizes endogenous virulence gene promoters to control the expression of in Staphylococcus aureus.
- A fluorescent reporter is integrated to monitor promoter activity, demonstrating the system's functionality in a clinical MRSA strain.
Essence
- The developed inducer-free vgp- system effectively regulates gene expression in Staphylococcus aureus using virulence gene promoters, avoiding the limitations of traditional inducer-dependent systems.
Key takeaways
- The vgp- system utilizes virulence gene promoters to control expression, enabling targeted gene regulation without external inducers.
- Testing showed that silencing the penicillin-binding protein 1 gene led to growth arrest, confirming the system's effectiveness in manipulating bacterial physiology.
- The system also successfully inhibited coagulation in rabbit plasma by targeting coagulase, demonstrating its potential applications in studying virulence factors.
Caveats
- Unexpected toxicity and plasmid instability were encountered during cloning, necessitating the use of alternative host strains for successful plasmid generation.
- The system's reliance on virulence gene promoters may introduce variability in expression levels, which could affect the consistency of experimental outcomes.
Definitions
- CRISPR interference (CRISPRi): A technique that uses a modified CRISPR system to inhibit gene expression without altering the DNA sequence.
- dCas9: A catalytically inactive form of the Cas9 protein used in CRISPR systems for gene regulation.
AI simplified
INTRODUCTION
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) interference (CRISPRi) is an efficient and versatile tool for selectively perturbing gene expression on a genome-wide scale and thus dissecting their role in bacterial physiology or pathogenesis (1). The applications of CRISPRi are getting increasingly advanced, e.g., allowing for simultaneous regulation of expression of multiple genes (1, 2) construction of genetic oscillators (3, 4) quantification of genome-wide fitness using CRISPRi-seq (5–8) and screening approaches that may identify novel antimicrobial targets, including those for synergistic drug combinations (9, 10).
In the previously published CRISPRi-system, dCas9 (more specifically Streptococcus pyogenes SpydCas9) expression is under control of promotors that are activated by exogenous inducers such as IPTG (isopropyl-β-D-thiogalactopyranoside) (Plac) (9, 11, 12) or tetracycline (Ptet) or its derivatives anhydrotetracycline (1) and doxycycline (7). The leaky character of Plac (9) and Ptet (13) promoters promote background dCas9 expression in the non-induced condition. Moreover, limitations in tissue and cell permeability render IPTG-inducible systems less suitable for use in certain model systems including animals (14). Undesired side-effects have been shown from the use of tetracyclines (15) or derivatives such as doxycycline (16) in mammalian cells, where they affect mitochondrial function (15) or can induce changes in gene transcription, metabolism, and cell proliferation (16), thus prompting caution for the use of these inducers in host-pathogen interaction studies.
Inducer-free alternatives CRISPRi system were developed, where dCas9 expression was controlled through strong constitutive gene promoters (17, 18). However, since it is well known that dCas9 provokes toxicity in many bacteria (19–24), its overexpression from strong constitutive promoters may cause undesirable phenotypes in Staphylococcus aureus cells. We reasoned that an alternative method for controlling CRISPRi system would be the use of virulence gene promoters. In such constructs, the dCas9 expression is switched on when the gene promoters are activated. Of note, the activity of many gene promoters has been shown not only to be conditional but also heterogeneous across cells within isogenic S. aureus subpopulations (25–28). This means that if dcas9 is controlled through an endogenous promoter with heterogeneous activity across a bacterial cell population, the activity of the CRISPRi system will be restricted to those cells where this promoter is active and enable a pathway for specific manipulation of cellular subpopulations.
Here, we report the development of a virulence gene promoter-induced CRISPRi system (vgp-CRISPRi) that is inducer-free and fluorescent reporter-labeled. In this system, dCas9 expression is controlled by the promoters of well-known S. aureus virulence genes autolysin (atl), fibronectin-binding protein A (fnbA), and coagulase (coa). In combination with single-guide RNAs (sgRNAs) target genes that are involved in diverse phenotypes, we present a proof-of-concept validation that the vgp-CRISPRi system is functional in the clinically relevant methicillin-resistant S. aureus (MRSA) strain USA300 LAC.
MATERIALS AND METHODS
Materials
Standard agarose, type LE for routine gel electrophoresis was purchased from BioNordika, Oslo, Norway. DNA Ladder, 1.0 Kb Plus (100 bp to 15,000 bp) was purchased from Invitrogen. Primers were obtained from Sigma Life Science (Oslo, Norway), and sequencing reactions were performed using BigDye Terminator V3.1 (Life Technologies) and analyzed at the Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. The Wizard Genomic DNA Purification Kit was purchased from Promega. E.Z.N.A. Plasmid DNA Mini Kit I (Q – spin) was purchased from Omega. Phusion High-Fidelity DNA Polymerase and DreamTaq Green PCR Master Mix were purchased from Thermo Scientific. All restriction enzymes were purchased from New England Biolabs and used according to the manufacturer’s instructions. MagExtractor-PCR and Gel Clean up were purchased from Toyobo (Osaka, Japan). Rabbit Plasma (for the detection of Staphylocoagulase) was purchased from Bio-Rad. Roswell Park Memorial Institute (RPMI) 1640 medium and heat-inactivated, sterile-filtered Fetal Bovine Serum (FBS), Dulbecco’s Phosphate-Buffered Saline, PBS (D8537), and DNase I were purchased from Sigma-Aldrich. RNAprotect Bacteria Reagent and RNeasy Mini Kit were purchased from QIAGEN (Oslo, Norway). High-Capacity cDNA Reverse Transcription Kit was purchased from Applied Biosystems. All other materials were purchased from an analytical-grade commercial source and used according to the manufacturer’s instructions.
Bacterial strains, media, growth conditions, plasmids, and transformation
The bacterial strains and plasmids used in this study are listed in Table 1 (S. aureus strains), S1 (Escherichia coli strains), and Table 2 (plasmids). The media used were lysogeny broth (LB; 244620, BD Difco), LB agar (244520, BD Difco), Tryptic Soy Broth (211825, BD Difco), and Tryptic Soy Agar (TSA; 236950, BD Difco). RPMI-1640 was purchased from Sigma-Aldrich (R8758) and used after supplementation with 10% FBS (F7524, Sigma-Aldrich) and is designated as RPMI+.
E. coli cells were grown in LB with shaking or on an LB agar plate at 37°C. Ampicillin was used at a final concentration of 100 µg/mL in LB or agar plates for the selection of recombinant plasmid-transformed E. coli colonies. S. aureus was routinely grown at 37°C on TSA plates or in TSB with shaking (220 rpm). Chloramphenicol (10 µg/mL) was used for the maintenance of the fluorescent reporter plasmids (pCM29- PsarA P1-GFP, pCM29-Patl-GFP, pCM29-PfnbA-GFP, and pCM29-Pcoa-GFP, see next section) in S. aureus. Erythromycin (5 µg/mL) and chloramphenicol (10 µg/mL) were used for the selection and maintenance of pLOW and pCM29 backbone plasmids, respectively, in S. aureus CRISPRi strains. IPTG was used as 250 µM (final concentration) for lac-promoter-induced dCas9 expression in the CRISPRi system. Plasmid pCM29-PsarA P1-GFP was provided by Dr. Alexander Horswill (University of Colorado School of Medicine, Colorado, USA) (31). Chemically competent E. coli IM08B cells were prepared according to reference (32) and routinely used for the transformation of constructed plasmid according to standard heat shock protocol (33). Chemically competent E. coli cells (TOP 10, NEB 5-alpha, NEBExpress Iq, and NEB 10-beta) were transformed according to the manufacturer’s instructions. S. aureus USA 300 LAC was transformed with dCas9 expression CRISPRi plasmid DNA isolated from S. aureus RN4220 (30) and fluorescent reporter plasmid DNA isolated from IM08B (34) by electroporation. The preparation of electrocompetent cells and electroporation were performed as described before (35).
| S. aureus | Genotype or description | Source or reference |
|---|---|---|
| USA300 LAC | Wild-type, coagulase-positive, community-acquired MRSA clone from the USA300 lineage, isolated from Los Angeles County (LAC) | () [29] |
| RN4220 | Restriction deficient derivative of NCTC8325-4 | () [30] |
| Fluorescent reporter strains | ||
| MR 9 | USA 300 LAC carrying pCM29-P-GFP, cmᴿatl | This study |
| MR 10 | USA 300 LAC carrying pCM29-P-GFP, cmᴿfnbA | This study |
| MR 11 | USA 300 LAC carrying pCM29-P-GFP, cmᴿcoa | This study |
| CRISPRi strains | ||
| MR 15 | USA 300 LAC carrying pLOW-P- d9, pCG248-sgRNA(), eryᴿ, cmᴿlaccaspbp1 | This study |
| MR 16 | USA 300 LAC carrying pLOW-P- d9, pCM29-PP1--sgRNA(), eryᴿ, cmᴿlaccassarAgfppbp1 | This study |
| MR 17 | USA 300 LAC carrying pLOW-P- d9, pVL2336-sgRNA(NTC),eryᴿ, cmᴿlaccas | This study |
| MR 18 | USA 300 LAC carrying pLOW-P- d9, pCM29-PP1--sgRNA(NTC), eryᴿ, cmᴿlaccassarAgfp | This study |
| MR 27 | USA 300 LAC carrying pLOW-P- d9, pCM29-P-sgRNA (NTC), eryᴿ, cmᴿatlcasatl-gfp | This study |
| MR 28 | USA 300 LAC carrying pLOW-P- d9, pCM29-P-sgRNA(), eryᴿ, cmᴿatlcasatl-gfppbp1 | This study |
| MR 29 | USA 300 LAC carrying pLOW-P- d9, pCM29-P-sgRNA (NTC), eryᴿ, cmᴿfnbAcasfnbA-gfp | This study |
| MR 30 | USA 300 LAC carrying pLOW-P- d9, pCM29--sgRNA(), eryᴿ, cmᴿfnbAcasPfnbA-gfppbp1 | This study |
| MR 31 | USA 300 LAC carrying pLOW-P- d9, pCM29-P-sgRNA(NTC), eryᴿ, cmᴿcoacascoa -gfp | This study |
| MR 32 | USA 300 LAC carrying pLOW-P- d9, pCM29-P-sgRNA(), eryᴿ, cmᴿcoacascoa-gfppbp1 | This study |
| MR 23 | USA 300 LAC carrying pLOW-P- d9, pCM29-PP1--sgRNA(), eryᴿ, cmᴿlaccassarAgfpcoa | This study |
| MR 24 | USA 300 LAC carrying pLOW-P- d9, pCM29-PP1--sgRNA(), eryᴿ, cmᴿatlcassarAgfpcoa | This study |
| MR 25 | USA 300 LAC carrying pLOW-P- d9, pCM29-PP1--sgRNA(), eryᴿ, cmᴿfnbAcassarAgfpcoa | This study |
| MR 26 | USA 300 LAC carrying pLOW- P- d9, pCM29-PP1--sgRNA(), eryᴿ, cmᴿcoacassarAgfpcoa | This study |
| Plasmids | Relevant characteristics | Source or reference |
|---|---|---|
| pCM29- PP1-GFPsarA | Plasmid carryingdownstream of the staphylococcal accessory regulator, SarA gene promoter P1, ampᴿ, cmᴿgfp | () [31] |
| pCM29- P-GFPatl | Plasmid carryingdownstream ofautolysin gene promoter, ampᴿ, cmᴿ gfp S. aureus 2 | This study |
| pCM29- P-GFPfnbA | Plasmid carryingdownstream offibronectin-binding protein A gene promoter, ampᴿ, cmᴿ gfp S. aureus 2 | This study |
| pCM29-P-GFPcoa | Plasmid carryingdownstream ofcoagulase gene promoter, ampᴿ, cmᴿ gfp S. aureus 2 | This study |
| pLOW- P9lac -dcas | Plasmid for IPTG-inducible expression of mutated Cas9 () downstream ofpromoter, ampᴿ, eryᴿ.dcas9lac | () [11] |
| pLOW- P-d9atlcas | Plasmid carryingdownstream ofautolysin gene promoter, ampᴿ, eryᴿ. dcas9 S. aureus 2 | This study |
| pLOW-P-d9fnbAcas | Plasmid carryingdownstream offibronectin-binding protein A gene promoter, ampᴿ, eryᴿ. dcas9 S. aureus 2 | This study |
| pLOW-P-d9coacas | Plasmid carryingdownstream ofcoagulase gene promoter, ampᴿ, eryᴿ. dcas9 S. aureus 2 | This study |
| pCG248-sgRNA ()pbp1 | Plasmid carrying sgRNA() expression cassette, ampᴿ, cmᴿ.pbp1 | () [11] |
| pCG248-sgRNA (NTC) | Plasmid carrying sgRNA() expression cassette, ampᴿ, cmᴿ.luc | () [11] |
| pVL2336-sgRNA ()coa | Plasmid carrying sgRNA() expression cassette, ampᴿ, cmᴿ.coa | This study |
| pCM29-PP1-GFP-sgRNA ()sarApbp1 | Plasmid carryingdownstream of the staphylococcal accessory regulator, SarA gene promoter P1 and sgRNA() expression cassette, ampᴿ, cmᴿ.gfppbp1 | This study |
| pCM29-P-GFP-sgRNA ()atlpbp1 | Plasmid carryingdownstream ofautolysin gene promoterand sgRNA() expression cassette, ampᴿ, cmᴿ. gfp S. aureus pbp1 2 | This study |
| pCM29--GFP -sgRNA()PfnbApbp1 | Plasmid carryingdownstream offibronectin-binding protein A gene promoterand sgRNA() expression cassette, ampᴿ, cmᴿ. gfp S. aureus pbp1 2 | This study |
| pCM29-P-GFP-sgRNA ()coapbp1 | Plasmid carryingdownstream ofcoagulase gene promoterand sgRNA() expression cassette, ampᴿ, cmᴿ. gfp S. aureus pbp1 2 | This study |
| pCM29-P-GFP-sgRNA (NTC)atl | Plasmid carryingdownstream ofautolysin gene promoterand sgRNA() expression cassette, ampᴿ, cmᴿ. gfp S. aureus luc 2 | This study |
| pCM29-P-GFP-sgRNA (NTC)fnbA | Plasmid carryingdownstream offibronectin-binding protein A gene promoterand sgRNA() expression cassette, ampᴿ, cmᴿ. gfp S. aureus luc 2 | This study |
| pCM29-PGFP-sgRNA (NTC)coa- | Plasmid carryingdownstream ofcoagulase gene promoterand sgRNA() expression cassette, ampᴿ, cmᴿ. gfp S. aureus luc 2 | This study |
| pCM29-PP1-GFP-sgRNA ()sarAcoa | Plasmid carryingdownstream of the staphylococcal accessory regulator, SarA gene promoter P1, and sgRNA() expression cassette, ampᴿ, cmᴿ.gfpcoa | This study |
Restriction enzyme digestion and ligation
Restriction enzyme digestion and ligation reactions were performed according to the manufacturer’s instructions (New England Biolabs). Briefly, a prepared restriction digestion reaction mixture containing sample DNA (1 µg), 10× rCutSmart buffer (5 µL), and restriction enzyme (10 units) in a total of 50 µL reaction volume with nuclease-free water was incubated at the optimum temperature for the given restriction enzyme for 2 hours. In this work, restriction digestions with BsmBI were carried out at 55°C, while all other restriction digestions were performed at 37°C. For restriction digestions of destination vectors, 1 µL calf intestinal alkaline phosphatase was added to the reaction after ~2 hours of incubation, followed by a subsequent incubation for ~30 min. Digested DNA was verified using agarose gel electrophoresis and purified either from the agarose gel or directly from the digestion reaction using MagExtractor-PCR and Gel Clean up kit (Toyobo, Osaka, Japan).
Digested vectors and inserts were ligated together using the T4 DNA ligase (New England Biolabs). The components of the reaction were mixed with a molar insert:vector ratio of 3:1. The reaction volume was 20 µL, using 2 µL of the supplied 10× reaction buffer and 1 µL T4 DNA ligase. Ligation reactions were carried out overnight at 16°C. Ligation reactions were stored at −20°C or directly transformed into the desired host.
Plasmid construction
Fluorescent reporter plasmids
Genomic DNA (gDNA) from S. aureus USA 300 LAC was isolated using the Wizard Genomic DNA Purification Kit. Using isolated gDNA as a template, PCR was performed using Phusion High-Fidelity DNA Polymerase to amplify the promoter region (non-coding gap sequence between the gene and its upstream gene) of autolysin, SAUSA 300_0955 (atl), fibronectin-binding proteins A, SAUSA 300_2441 (fnbA), and coagulase, SAUSA 300_0224 (coa) with their respective primer sets RM 1/2, RM 3/4, and RM 7/8 (Table S2). The PCR-amplified fragments and the vector pCM29-PsarA P1-GFP (31) were both digested with KpnI and PstI. Digested fragments and vector backbone pCM29-GFP were purified after agarose gel electrophoresis and ligated by T4 DNA Ligase (New England Biolabs) to produce the pCM29-Patl-GFP, pCM29-PfnbA-GFP, and pCM29-Pcoa-GFP construct in which a Green Fluorescent Protein (GFP) reporter is placed under control of promoter Patl, PfnbA, and Pcoa, respectively. The ligation reaction mix was transformed into E. coli IM08B, and cells were plated on LB agar plates containing 100 µg/mL ampicillin, and the correct construct was verified by PCR and sequencing.
dCas9 expression low-copy number pLOW-dcas9 plasmid
Gene promoters (Patl, PfnbA, and Pcoa) were amplified by PCR using previously constructed fluorescent reporter plasmids, pCM29-Patl-GFP, pCM29-PfnbA-GFP, and pCM29-Pcoa-GFP as the template DNA, respectively, with their primer sets RM 11/12, RM 13/14, and RM 15/16 (Table S2). The PCR amplified fragments and the vector pLOW-Plac-dcas9 (11) were both digested with AvrII and SalI. Digested fragments and vector backbone pLOW-dcas9 were purified after agarose gel electrophoresis and ligated by T4 DNA Ligase (New England Biolabs) to produce the pLOW-Patl-dcas9, pLOW-PfnbA-dcas9, and pLOW-Pcoa-dcas9 constructs where dcas9 is placed downstream of each selected gene promoter. The ligation reaction mix was transformed into E. coli NEB10-beta, and cells were plated on LB plates containing 100 µg/mL ampicillin, and the correct construct was verified by restriction mapping, PCR, and sequencing. All plasmids used in this study are listed in Table 2.
The sgRNA expression high-copy number pCM29-PsarA P1-GFP plasmid
A sgRNA construct, consisting of a 20 nt base-pairing region of targeted genes (pbp1, coa) or a no-target control (NTC) sequence originally designed to target the luciferase gene (luc) along with their Cas9-handle region, located downstream of a synthetic, constitutive promoter P3 in the vector pVL2336-sgRNA/pCG248-sgRNA (9, 11) was cut out using EcoRI. The fragments were ligated into the corresponding sites of vector pCM29-PsarA P1-GFP (31), pCM29-Patl-GFP, pCM29-PfnbA-GFP, and pCM29-Pcoa-GFP by T4 DNA Ligase (New England Biolabs) to construct pCM29-PsarAP1-GFP-sgRNA(pbp1), pCM29-PsarAP1-GFP-sgRNA(coa), pCM29-Patl-GFP-sgRNA(pbp1), pCM29-Patl-GFP-sgRNA(NTC), pCM29-PfnbA-GFP-sgRNA(pbp1), pCM29-PfnbA-GFP-sgRNA(NTC), pCM29-Pcoa-GFP-sgRNA(pbp1), and pCM29-Pcoa-GFP-sgRNA (NTC). The ligation reaction mix was transformed into E. coli IM08B, and cells were plated on LB agar plates containing 100 µg/mL ampicillin, and the correct construct was verified by PCR and sequencing. The sequences of the sgRNA base-pairing regions are given in Table S3.
Bacterial growth and GFP fluorescence analysis
Bacterial growth (OD600) and GFP fluorescence were measured in a microplate assay on a Synergy H1 Hybrid Reader (BioTek). Bacterial cells were cultivated at 37°C overnight with shaking (220 rpm). Cell cultures from E. coli WT (IM08B or NEB10-beta), S. aureus USA 300 WT, and their fluorescent reporter strains, MR 1–11 (Table 1; Table S1), and fluorescently labeled (MR 16, 27–32) and non-labeled (MR 15) CRISPRi strains (Table 1) were diluted to an OD600 of 0.1 in their respective fresh medium (TSB or RPMI+ for S. aureus and LB for E. coli strains). Two microliter of these diluted overnight cultures was inoculated into 298 µL of each respective fresh medium in a 96-well flat-bottom polystyrene tissue culture plate (Falcon). The plate was incubated directly in a Synergy H1 Hybrid Reader (BioTek) microtiter plate reader at 37°C with constant double orbital shaking (400 rpm for 5 s) in between measurements. Optical density (OD600) and GFP fluorescence (excitation 479 and emission 520) were measured at 1-hour intervals for up to 24 hours. GFP fluorescence was recorded as relative fluorescence units (RFUs, i.e., relative to the internal standard in the instrument). The OD600 and GFP fluorescence values from three biological replicates that were each derived from three technical replicates were averaged and corrected from blank wells containing only medium for each strain.
RNA purification, reverse transcription, and quantitative PCR
The overnight cultures of coagulase-interfering CRISPRi strains MR 23–26 (Table 1) and their respective non-targeting control strains MR 27, 29, and 31 (Table 1) were diluted to an OD600 of 0.1 in fresh TSB or RPMI+ and grown at 37°C for 6 hours. Silencing of the coa gene in the Plac-based strain MR23 was induced by adding IPTG to a final concentration of 250 µM. Cells from each culture were diluted in PBS (D8537, Sigma) and adjusted to McFarland 0.5 (i.e., about 108 cells/mL). Subsequently, cells were treated with 2 × volume of RNAprotect Bacteria Reagent (QIAGEN) for 10 min at room temperature and collected by centrifugating for 10 min at 5,000 × g. Lysostaphin, 1 µg/µL, and lysozyme, 10 µg/µL, were added as final concentration to the suspended solution and incubated at 37°C for 30 minutes for lysis of bacterial cells before RNA isolation. RNA extraction was performed using a RNeasy Mini Kit (QIAGEN). The remaining DNA in the isolated RNA was degraded by DNase I (Sigma-Aldrich). DNA-free RNA was subjected to reverse transcription (RT) with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RNA extraction, DNase treatment, and RT were performed according to the manufacturer’s direction. Synthesized cDNA solution was 10- and 10,000-fold diluted with RNase-free water, and 2 µL of the diluted cDNA solution was subjected to real-time PCR assay performed with PowerTrack SYBR Green Master Mix (Applied Biosystems) containing 0.5 µM each primer set. After cycling, melt curves analysis was performed between 70°C and 90°C. All quantitative PCR (qPCR) data were analyzed using LightCycler 96 system software version 1.1 (Roche Diagnostics). Relative coagulase expression was calculated according to the 2−∆∆Ct method after normalization by 16S rRNA (rrsA). The real-time PCR primers are listed in Table S2. qPCR was performed in two technical replicates from their three biological replicates.
Coagulation assays
The overnight cultures of coagulase-interfering CRISPRi strains MR 23–26 (Table 1) and their respective non-targeting control strains MR 27, 29, and 31 (Table 1) were diluted to an OD600 of 0.1 in fresh TSB or RPMI+ and grown at 37°C for 18 hours. Silencing of the coa gene in the control strain MR23 [USA300 LAC carrying pLOW-Plac-dcas9, pCM29-PsarA-P1 gfp-sgRNA (coa); Table 1] was induced by adding IPTG to a final concentration of 250 µM. Cells from each culture were diluted in PBS (D8537, Sigma-Aldrich) and adjusted to McFarland 0.5 (i.e., about 108 cells/mL). Subsequently, 1 mL of each McFarland-adjusted culture was added to 0.5 mL rabbit plasma (Bio-Rad). The samples were incubated in a water bath at 37°C for 4 hours. The level of coagulation was verified by tipping the tubes to a 45° angle. A negative control (NC) sample contained medium only. A test was considered positive if the plasma in the tube formed a coherent clot. All experiments were repeated three times as independent biological replicates to examine the reproducibility.
RESULTS
Design of a vgp-CRISPRi system for S. aureus
In the previously published staphylococcal CRISPRi-system, dcas9 [S. pyogenes (SpydCas9)] expression is controlled by an IPTG-inducible lac promoter in the low copy number pLOW-dcas9 plasmid, and sgRNA is expressed by constitutive P3 promoter in the vector pVL2336-sgRNA (or equivalent vector pCG248-sgRNA) (9, 11, 12). To generate an inducer-independent system for S. aureus, we replaced the lac promoter with S. aureus-specific virulence gene promoters in the pLOW plasmid (Fig. 1A through C). We selected well-known virulence gene promoters controlling the expression of genes encoding autolysin (Patl), fibronectin-binding protein A (PfnbA), and coagulase (Pcoa). Since the activity levels of endogenous virulence gene promoters are dynamic, there is condition-dependent variation as to when the promoter is activated and dcas9 is expressed, which is a precondition for the activity of the CRISPRi system. To address this question, we incorporated a fluorescent reporter gene into the CRISPRi system by placing gfp (into the sgRNA-expressing plasmid) under the control by the same promoter as dcas9.
During the generation of these constructs, we encountered technical challenges caused by the unexpected activity of S. aureus gene promoters in E. coli (Fig. S1) prompting dCas9-related toxicity and plasmid instability in the E. coli cloning host IM08B (Fig. S2), a strain that methylates the plasmids to conveniently allow direct transformation into many S. aureus lineages including USA300 LAC. These pitfalls were bypassed by identifying E. coli NEB10-beta as an alternative cloning host that is less susceptible to dCas9-mediated toxicity (Fig. S2). Isolated plasmids from NEB10-B could then be successfully electroporated into S. aureus RN4220 (to enable correct methylation), repurified, and electroporated into the clinical MRSA-isolate USA300 LAC, providing a viable strategy for generating S. aureus gene-promoter-driven CRISPRi constructs in S. aureus.
Overview of the IPTG-inducible and the inducer-free, fluorescent reporter-labeled virulence gene promoter-activated CRISPRi system. () The plasmids used in the IPTG-inducible CRISPRi system. () Schematic overview of the activation of the CRISPRi system incells after IPTG induction. () Plasmids associated with the vgp-CRISPRi system. dCas9 expression is controlled by a virulence gene promoter (Px) on the pLOW-Px-dCas9 plasmid. The sgRNA is expressed from a pCM29-plasmid under control of the constitutive P3 promoter. This plasmid also carries agene that can be placed under control of a virulence gene promoter of interest. () Schematic representation of the activation of the vgp-CRISPRi system. The schematic exemplifies the scenario whenandunder control of the same promoter Px. Based on the nature of the promoter and experimental conditions, the promoter may be (i) homogeneously or (ii) heterogeneously activated under the conditions of interest. As a consequence, the CRISPRi system is activated either (i) in the entire cell population or (ii) in a subpopulation only. A B C D S. aureus gfp dcas9 gfp
Evaluating dynamic virulence gene promoter activities in S. aureus
We first evaluated dynamic differences in the selected S. aureus promotors under different growth phases and media conditions. We recorded 24-hour-growth curves and fluorescent signals of pCM29-GFP-based fluorescent reporter strains (strains MR 9–11, Table 1) in default bacteriological culture media (TSB) as well as RPMI-1640 supplemented with 10% FBS (RPMI+), a mammalian cell culture medium that mimics the composition of human body fluids (36, 37). Compared to a PsarAP1 reporter, all strains showed low levels of fluorescence in TSB that was increasing throughout the exponential and stationary phase (Fig. 2). Interestingly, the Pcoa- reporter strain showed a greater than sixfold increase in GFP signal during exponential growth in RPMI+ indicating the differential activity of these promoters in different environments (Fig. 2). Since Pcoa showed the highest activity levels across the conditions tested, we considered it a suitable promoter for a proof-of-principle experiments with the vgp-CRISPRi system.
Differential activation of virulence gene promoters in. Overlays of growth curves (OD) and GFP fluorescence levels (in RFU) of ()LAC WT and () pA-GFP, () P-GFP, () P-GFP, and () PA-GFP fluorescent reporter strains. Cultures were grown either in (i) TSB or (ii) cell culture medium RPMI+. Data show means ± SD of= 3 biological replicates (each recorded with three technical replicates). S. aureus S. aureus sar coa atl fnb n 600 A B C D E
virulence gene promoter-driven CRISPRi constructs are functional in S. aureus S. aureus
Classical CRISPRi systems are based on the IPTG-inducible dcas9 expression pLOW plasmid and sgRNA-target sequence on pVL2236 plasmid (strain MR15; Table 1). We first tested if the pCM29-PsarA-P1-gfp-based sgRNA plasmids were functional (like the pVL2236 plasmid) in combination with the pLOW plasmid in strain MR16 (Table 1). We chose to target the gene encoding the essential protein PBP1, which has been reported to result in a growth inhibition phenotype upon induction (11). After IPTG induction, a characteristic growth halt for up to 10 hours was observed for both strains, MR15 (Fig. 3A) and MR16 (Fig. 3B). Because strain MR 16 exhibited a similar outcome to MR 15, it indicates that the pCM29-PsarA-P1-gfp-based sgRNA plasmid is also functional, like the pVL2236 plasmid, in the IPTG-inducible system. Interestingly, growth resumption coincided with a decline in GFP signal (controlled by PsarA-P1) after IPTG induction in strain MR16 (Fig. 3B).
Finally, to investigate if dcas9 expression under control of virulence gene promoters leads to similar growth arrest when sgRNA is targeting pbp1, we generated a CRISPRi strain (MR32; Table 1) carrying pLOW-Pcoa-dcas9 and pCM29-Pcoa-gfp-sgRNA(pbp1), in which dcas9 and gfp are controlled by the coa-promoter, whereas sgRNA expression is driven by the constitutive P3 promoter (Fig. 1). Indeed, this strain (MR32) also showed pronounced growth inhibition with declined GFP signal in both TSB (Fig. 3C) and RPMI+ (Fig. 3D) when compared to a non-target control strain (MR31; Table 1). CRISPRi constructs where dcas9 (and gfp) was controlled by the Patl and PfnbA and showed similar temporary growth arrest with declined GFP signal when used in combination with sgRNA (pbp1; Fig. S3). Collectively, these observations can be attributed to the emergence of loss-of-function mutations in the CRISPRi system that are commonly observed when targeting essential genes (6, 8, 38).
Of note, the growth patterns of strains with a non-targeted sgRNA of the classical IPTG-inducible system (MR17 and 18; Table 1) and the vgp-CRISPRi system (MR 27, 29, and 31, Table 1) in both TSB and RPMI+ medium were identical, regardless of whether dCas9 expression was induced with IPTG or not, or which promoter was used to control dCas9 expression (Fig. S4). These data suggest that dCas9 expression per se does not affect the growth of S. aureus. However, compared to the WT, all mentioned CRISPRi strains showed a noticeable growth delay in both TSB and RPMI and a reduction in growth rate in TSB (Fig. S4), which might be attributed to plasmid carriage and growth in the presence of antibiotics selection.
Silencing of1 in vgp-CRISPRi induces growth inhibition inLAC. () Growth (OD) of the indicated classical pVL2336-based inducible CRISPRi strains grown in TSB in the presence or absence of IPTG (250 µM). () Overlay of the growth curve (OD) and GFP fluorescence levels (in RFU) of the indicated CRISPRi strains grown in TSB in the presence or absence of IPTG (250 µM) over time. () Overlay of growth (OD) and GFP fluorescence (RFU) over time of the indicated vgp-CRISPRi strains grown in () TSB or () RPMI+.andexpression was controlled by the Ppromoter, sgRNAs targeted either the essential peptidoglycan biosynthesis gene(monocistronic) inducing growth inhibition or an NTC sequence derived from the luciferase gene. Data show mean ± SD of= 3 biological replicates (each recorded with three technical replicates). pbp S. aureus dcas9 gfp coa pbp1 n A B C and D C D 600 600 600
Virulence gene promoter-driven CRISPRi strains allow specific and robust interference withgene expression and coagulase function coa
Finally, we aimed to demonstrate that vgp-CRISPRi is suitable to interfere with specific virulence-associated phenotypes. We focused on coagulase, which converts fibrinogen to fibrin thus inducing clotting of blood plasma. We constructed CRISPRi strains with coa as the sgRNA target and dCas9 expression under the control of the Plac, Patl, PfnbA, and Pcoa promoters, respectively (MR23–26; Table 1). We first analyzed the effect on gene expression. qPCR analysis revealed that vgp-CRISPRi strains in which dcas9 expression was driven by either Patl, PfnbA, or Pcoa P showed reduced coa levels that were similar to those achieved with the IPTG inducible system in both TSB and RPMI+ (Fig. 4). Having confirmed the effect on gene expression, we proceeded to test if silencing of the coa gene was sufficient to interfere with the biological function of coagulase. While the addition of WT bacteria to rabbit plasma induced visible clots after 4 hours, no clotting was observed for either of these inducer-free constructs (nor the IPTG-inducible CRISPRi strains with IPTG induction) suggesting successful inhibition of coagulation by knock-down of the coa gene (Fig. 5). Non-target controls showed coagulation levels comparable to the WT. The same outcome was achieved regardless of whether bacteria were originally cultivated in TSB or RPMI+, suggesting that all tested promoters were sufficiently activated for the functioning of vgp-CRISPRi system.
Silencing ofexpression by vgp-CRISPRi strains. Repression ofmRNA of the indicated vgp-CRISPRi strains grown in () TSB or () RPMI+. The sgRNA target wasor an NTC derived from the luciferase gene, and dCas9 expression was controlled by the P, P, P, and Ppromoters as indicated. Before total mRNA isolation, strains were grown at 37°C for 6 hours in fresh TSB or RPMI+ with IPTG as indicated. Relative coagulase expression was calculated after normalization by 16S rRNA (rrsA). Data show mean ± SD of= 3 biological replicates (each recorded with two technical replicates). Significance was tested for each construct against its NTC control pair by unpaired, two-tailed Studentstest.< 0.01 and< 0.0001. coa coa coa lac atl fnbA coa n t P P A B ∗∗ ∗∗∗∗
Silencing ofby vgp-CRISPRi strains prevents plasma coagulation. The figure shows photographs of culture tubes 4 hours after adding different CRISPRi strains to rabbit plasma. The tubes were tilted to the side, and coherent clot formation is indicative of coagulation (arrowheads). The sgRNA target wasor an NTC derived from the luciferase gene, dCas9 expression controlled by the P, P, P, and Ppromoters as indicated. Before the addition of plasma, strains were grown at 37°C for 18 hours in fresh TSB or RPMI+ with or without IPTG as indicated. The figure is representative for three biological replicates. The NC contained medium (RPMI+ or TSB) with rabbit plasma suspension, and WT representsUSA 300 LAC strain. coa coa lac atl fnbA coa S.aureus
DISCUSSION
Here, we have developed an alternative CRISPRi strategy, in which dCas9 expression is controlled through specific S. aureus virulence gene promoters, and we have shown that it is functional in S. aureus. The phenotypes induced by gene silencing (temporary growth arrest by silencing of pbp1, interference with coa expression, and coa-dependent coagulation of plasma) using the vgp-CRISPRi system were qualitatively and quantitatively similar to effects achieved with the classical IPTG-inducible system. Since activity levels of the investigated promoters (Pcoa, Patl, and PfnbA) are low in comparison to constitutive promoter (PsarA P1) and variable across growth stages and media conditions, the similar outcome suggests that relatively low levels of dCas9 expression are sufficient for robust activation of the CRISPRi system across the conditions tested. These data position the vgp-CRISPRi system as an alternative for studying gene function in experimental systems for which the use of exogenous inducers such as IPTG or antibiotics has pharmacokinetic limitations or induces off-target effects.
During the construction of this vgp-CRISPRi system, we encountered unexpected dCas9 toxicity and plasmid instability issues during cloning in E. coli. We speculate that the instability of the dCas9-expression plasmids in E. coli IM08B is caused by the expression of dCas9 from S. aureus gene promoters in E. coli. This leads to toxic levels of dCas9 for this strain, which results in the selection of loss-of-function mutations in the CRISPRi plasmids. Here, we were able to avoid dCas9 toxicity-dependent issues in plasmid stability by testing alternative cloning host strains and established a viable cloning strategy using NEB-10beta. The need to transform the resulting CRISPRi plasmids first into S. aureus RN4220 makes this approach more time-consuming compared to the use of an E. coli methylation host such IM08B that allows for direct transformation into relevant S. aureus strains. We, therefore, suggest that a close examination of dCas9-toxicity of other strains of the IMxxB series (34) may identify suitable strains that may expedite vgp-CRISPRi strain generation. Consistent with previous studies (9, 11), we did not observe a toxic effect related to dCas9 expression in S. aureus. However, compared to the WT all strains carrying the CRISPRi plasmids (regardless of dCas9 expression) showed delayed growth and a reduced growth rate in specific media. This highlights the importance of NTC controls to avoid misinterpretations and false attributions of such growth defects to repression of target genes.
Classical CRISPRi setups are used to study a “gene-of-interest” through silencing with an appropriate sgRNA, whereas the promoter that controls dCas9 is merely used as means-to-an-end. The addition of an external inducer will yield a homogeneous activation of the classical CRISPRi system in bulk populations not considering the complexity associated with phenotypic heterogeneity within a cell population. Since it is emerging that the expression of many virulence genes indeed is heterogeneous across cells within isogenic populations (39–41), the development of vgp-CRISPRi promises to target and restrict the gene knock-down to specific subpopulations in which a “promoter-of-interest” is active. Thus, the vgp-CRISPRi system may hold promise for dissecting the role of isogenic bacterial subpopulations.
To enable visual tracking of relevant promoter activities over time and across cell populations, we incorporated a GFP reporter. The fluorescent reporter gene was included in the pCM29-based sgRNA plasmid where it was placed under control of the same virulence gene promoter that expresses dCas9 on the pLOW plasmid. Thus, both dCas9 and GFP will be expressed when the virulence gene promoter is active. However, when the sgRNA targets the essential pbp1, the GFP signal declines once cells overcome the initial CRISPRi-induced growth arrest. We speculate that the selective pressure of interfering with essential gene-induced mutations in the plasmid that leads to both the inactivation of the CRISPRi system and—as a bystander—the GFP reporter signal.
This system may be developed further by also replacing the constitutive P3 promoter that controls the sgRNA with an additional endogenous gene promoter, effectively creating an AND-gate scenario where activation of the CRISPRi system would require the simultaneous activity of two endogenous promoters. We believe that the adaptability and flexibility of the vgp-CRISPRi system will enable diverse application studies aimed at deciphering the functional dynamics of bacterial cell populations at the host-pathogen interface and provide a pathway for the functional engineering of bacterial cell populations.
ACKNOWLEDGMENTS
We would like to thank Zhian Salehian and Marita Torrissen Mårli, NMBU, for their help with cloning and strain construction.
This work was funded by a Center for New Antibacterial Strategies (CANS) starting-grant through the Trond-Mohn Foundation to C.S.L. M.K. is supported by JPIAMR (Research Council of Norway grant 296906).
Experiment design: all authors. Data acquisition: R.M. Data analysis: all authors. Original manuscript draft: R.M. Manuscript writing: all authors. Concept: R.M. and C.S.L. Funding: C.S.L.
Contributor Information
Roni Miah, Email: roni.miah@uit.no.
Christian S. Lentz, Email: Christian.s.lentz@uit.no.
Rebecca S. Shapiro, University of Guelph, Ontario, Canada
SUPPLEMENTAL MATERIAL
The following material is available online at https://doi.org/10.1128/spectrum.00602-24↗.
ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse.